Although sometimes risky and volatile, the biotech industry is an excellent place to find stocks that can generate steady returns for years. That's because these companies tend to offer products that aren't optional for their consumers: lifesaving drugs.

Obviously, not all companies in this industry can deliver significant capital appreciation. But two that stand good chances right now are Bristol Myers Squibb (NYSE: BMY) and (NYSE: NVS). Neither stock has performed particularly well this year, but there's good reason to think that will change. 

Bristol Myers Squibb has a problem that even the most prominent drugmakers face every now and then. The company lost patent exclusivity for one of its top-selling products, Revlimid, last year.

Continue reading

Source Fool.com